CA3119403C - Artificial hla-positive feeder cell lines for nk cells and uses thereof - Google Patents

Artificial hla-positive feeder cell lines for nk cells and uses thereof Download PDF

Info

Publication number
CA3119403C
CA3119403C CA3119403A CA3119403A CA3119403C CA 3119403 C CA3119403 C CA 3119403C CA 3119403 A CA3119403 A CA 3119403A CA 3119403 A CA3119403 A CA 3119403A CA 3119403 C CA3119403 C CA 3119403C
Authority
CA
Canada
Prior art keywords
cells
cell
car
hla
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3119403A
Other languages
English (en)
French (fr)
Other versions
CA3119403A1 (en
Inventor
Achim TEMME
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Dresden
Original Assignee
Technische Universitaet Dresden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Dresden filed Critical Technische Universitaet Dresden
Publication of CA3119403A1 publication Critical patent/CA3119403A1/en
Application granted granted Critical
Publication of CA3119403C publication Critical patent/CA3119403C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3119403A 2018-11-23 2019-11-22 Artificial hla-positive feeder cell lines for nk cells and uses thereof Active CA3119403C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18208092.9A EP3656851A1 (en) 2018-11-23 2018-11-23 Artificial hla-positive feeder cell lines for nk cells and uses thereof
EP18208092.9 2018-11-23
PCT/EP2019/082283 WO2020104676A1 (en) 2018-11-23 2019-11-22 Artificial hla-positive feeder cell lines for nk cells and uses thereof

Publications (2)

Publication Number Publication Date
CA3119403A1 CA3119403A1 (en) 2020-05-28
CA3119403C true CA3119403C (en) 2023-02-07

Family

ID=64664021

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3119403A Active CA3119403C (en) 2018-11-23 2019-11-22 Artificial hla-positive feeder cell lines for nk cells and uses thereof

Country Status (5)

Country Link
US (1) US11578307B2 (https=)
EP (2) EP3656851A1 (https=)
JP (1) JP7450892B2 (https=)
CA (1) CA3119403C (https=)
WO (1) WO2020104676A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018060351A1 (en) * 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
KR20220095228A (ko) * 2019-11-06 2022-07-06 베이롤 칼리지 오브 메드신 암의 t 세포 치료를 위한 세포독성 효과기 기억 t 세포를 생산하는 방법
EP4163366A4 (en) * 2020-06-09 2024-08-21 Samsung Life Public Welfare Foundation GENETICALLY MODIFIED CELL LINE FOR ACTIVATION AND AMPLIFICATION OF NK CELLS AND USE THEREOF
CN112048482A (zh) * 2020-09-09 2020-12-08 广东昭泰体内生物医药科技有限公司 一种nk样细胞的培养方法
US12264184B2 (en) * 2021-02-23 2025-04-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. DAP12 constructs and their use to enhance DC vaccines and immunotherapies
US20230149464A1 (en) * 2021-11-18 2023-05-18 Janssen Biotech, Inc. Feeder free cell culture methods for expanding natural killer cell preparations
WO2023096352A1 (ko) * 2021-11-25 2023-06-01 사회복지법인 삼성생명공익재단 Hla-e를 발현하도록 유전적으로 조작된 배양보조세포주, 및 그의 용도
CN117343906A (zh) * 2022-07-04 2024-01-05 上海优卡迪生物医药科技有限公司 表达重组抗原蛋白的饲养细胞及其制备方法和应用
CN115725509B (zh) * 2022-12-09 2025-07-04 上海贝斯昂科生物科技有限公司 一种基因工程细胞的制备及其在nk细胞体外扩增中的应用
KR102669705B1 (ko) * 2023-02-24 2024-06-10 이엔셀 주식회사 제대혈 유래 자연 살해 세포의 확장배양방법
CN116286666B (zh) * 2023-05-15 2023-08-04 成都云测医学生物技术有限公司 滋养层细胞及其制备方法、应用和扩增nk细胞的方法
AU2024351310A1 (en) * 2023-09-25 2026-03-26 Legend Biotech Ireland Limited Modified immune cells and calcineurin inhibitors and uses thereof
GB202317912D0 (en) * 2023-11-23 2024-01-10 Univ College Cardiff Consultants Ltd Viral-based immuno therapeutic
KR20250153112A (ko) * 2024-04-16 2025-10-24 주식회사 유씨아이테라퓨틱스 자연살해세포의 증폭 및 형질 도입 효율 증진용 피더 세포

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
JPH0628570B2 (ja) 1986-02-13 1994-04-20 雪印乳業株式会社 カプセル体の製造方法及び装置
EP0301777A1 (en) 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
US5089272A (en) 1989-03-29 1992-02-18 Snow Brand Milk Products Co., Ltd. Process for producing capsules having a permeability-controllable membrane
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
ATE218893T1 (de) 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
WO2012131419A1 (en) * 2011-03-25 2012-10-04 Txcell Method for using regulatory t cells in therapy
WO2012146702A1 (en) * 2011-04-28 2012-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing accessory cells and uses thereof for preparing activated nk cells
EP2893003B1 (en) * 2012-09-04 2021-03-31 Inven2 AS Selective and controlled expansion of educated nk cells
EP3021853A1 (en) * 2013-07-18 2016-05-25 Baylor College Of Medicine Method of enhancing potency of immune cells
EP3223856B1 (en) * 2014-10-27 2025-09-24 University of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
GB201616237D0 (en) * 2016-09-23 2016-11-09 Univ Oslo Hf Modulation of function of immune effector cells

Also Published As

Publication number Publication date
EP3884040A1 (en) 2021-09-29
WO2020104676A1 (en) 2020-05-28
US11578307B2 (en) 2023-02-14
JP2022513116A (ja) 2022-02-07
JP7450892B2 (ja) 2024-03-18
US20210355446A1 (en) 2021-11-18
EP3656851A1 (en) 2020-05-27
CA3119403A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
CA3119403C (en) Artificial hla-positive feeder cell lines for nk cells and uses thereof
JP7657474B2 (ja) Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
US11845794B2 (en) CS1-specific chimeric antigen receptor engineered immune effector cells
CN113474450A (zh) 产生工程化细胞的方法以及所述工程化细胞的组合物
EP3737741A1 (en) Method for transducing cells with a viral vector for the expression of a chimeric antigen receptor (car) or transgenic t-cell receptor (tcr)
KR20200108278A (ko) 조작된 ｔ 세포의 조성물을 제조하는 방법
KR20180082493A (ko) Traf-유도 도메인을 함유하는 키메라 수용체 및 관련 조성물 및 방법
EP4146703A2 (en) Chimeric antigen receptors (cars) targeting natural killer cells
Chen et al. The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments
CN115768464A (zh) 产生工程化记忆样nk细胞及其组合物的方法
CN115916963A (zh) 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
WO2018169922A2 (en) Chimeric antigen receptors for melanoma and uses thereof
CN116917313A (zh) 靶向hiv感染细胞的嵌合抗原受体t细胞
US20220280564A1 (en) Methods for expanding t cells for the treatment of cancer and related malignancies
WO2024042318A1 (en) Chimeric antigen receptor (car) to a tcr beta-chain variable region
WO2025090933A1 (en) Methods and compositions comprising a type i interferon (ifn1) inhibitor
WO2023227594A1 (en) Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
CA2910666C (en) Cs1-specific chimeric antigen receptor engineered immune effector cells
BR102023027472A2 (pt) Polinucleotídeo, receptor de antígeno quimérico, vetor, composição, método para produção de célula imune efetora modificada e uso do polinucleotídeo
Lehner et al. Redirecting T Cells to Ewing’s Sarcoma Family of Tumors by a Chimeric NKG2D Receptor
HK1218925B (en) Cs1-specific chimeric antigen receptor engineered immune effector cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210510

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241111

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241111

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251110

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251110